These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17143114)

  • 1. European Society of Urogenital Radiology guidelines on contrast media application.
    Thomsen HS;
    Curr Opin Urol; 2007 Jan; 17(1):70-6. PubMed ID: 17143114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to avoid CIN: guidelines from the European Society of Urogenital Radiology.
    Thomsen HS
    Nephrol Dial Transplant; 2005 Feb; 20 Suppl 1():i18-22. PubMed ID: 15705944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media.
    Thomsen HS
    Eur J Radiol; 2006 Dec; 60(3):307-13. PubMed ID: 16965884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESUR guidelines on contrast media.
    Thomsen HS; Morcos SK;
    Abdom Imaging; 2006; 31(2):131-40. PubMed ID: 16447092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiologists' knowledge and perceptions of the impact of contrast-induced nephropathy and its risk factors when performing computed tomography examinations: a survey of European radiologists.
    Reddan D; Fishman EK
    Eur J Radiol; 2008 May; 66(2):235-45. PubMed ID: 17728089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Society of Urogenital Radiology guidelines on administering contrast media.
    Morcos SK; Thomsen HS;
    Abdom Imaging; 2003; 28(2):187-90. PubMed ID: 12592465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.
    Fishman EK; Reddan D
    Acta Radiol; 2008 Apr; 49(3):310-20. PubMed ID: 18365820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the risk of iodine-based and MRI contrast media administration: recommendation for a questionnaire at the time of booking.
    Morcos SK; Bellin MF; Thomsen HS; Almén T; Aspelin P; Heinz-Peer G; Jakobsen JA; Liss P; Oyen R; Stacul F; van der Molen AJ; Webb JA;
    Eur J Radiol; 2008 May; 66(2):225-9. PubMed ID: 18342469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular gadolinium-based contrast media: an overview.
    Bellin MF; Van Der Molen AJ
    Eur J Radiol; 2008 May; 66(2):160-7. PubMed ID: 18358659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequently asked questions: iodinated contrast agents.
    Bettmann MA
    Radiographics; 2004 Oct; 24 Suppl 1():S3-10. PubMed ID: 15486247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M; Uder M
    Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are referring clinicians aware of patients at risk from intravenous injection of iodinated contrast media?
    Konen E; Konen O; Katz M; Levy Y; Rozenman J; Hertz M
    Clin Radiol; 2002 Feb; 57(2):132-5. PubMed ID: 11977947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.
    Peak AS; Sheller A
    Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guideline 'Precautionary measures for contrast media containing iodine'].
    van Dijk Azn R; Wetzels JF; ten Dam MA; Aarts NJ; Schimmelpenninck-Scheiffers ML; Freericks MP; Said SA; Geenen RW; Stuurman A; van Everdingen JJ
    Ned Tijdschr Geneeskd; 2008 Mar; 152(13):742-6. PubMed ID: 18461890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contrast media in urogenital radiology].
    Foschi N; Totaro A; Brescia A; Gulino G; Bassi PF
    Urologia; 2009; 76(1):10-8. PubMed ID: 21086324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: center case review.
    Lauenstein TC; Salman K; Morreira R; Tata S; Tudorascu D; Baramidze G; Singh-Parker S; Martin DR
    J Magn Reson Imaging; 2007 Nov; 26(5):1198-203. PubMed ID: 17969162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.